AAPL 172.03 +0.12 (+0.07%)MSFT 107.14 +0.57 (+0.53%)FB 130.65 -2.52 (-1.89%)ZNGA 3.95 +0.07 (+1.68%)NVDA 133.37 -0.29 (-0.22%)WBA 68.22 +0.16 (+0.24%)GOOG 1029.8 -7.78 (-0.75%)PIH 4.14 +0.25 (+6.43%)
AAPL 172.03 +0.12 (+0.07%)MSFT 107.14 +0.57 (+0.53%)FB 130.65 -2.52 (-1.89%)ZNGA 3.95 +0.07 (+1.68%)NVDA 133.37 -0.29 (-0.22%)WBA 68.22 +0.16 (+0.24%)GOOG 1029.8 -7.78 (-0.75%)PIH 4.14 +0.25 (+6.43%)

Cash Flow ANAB Quote AnaptysBio

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
NetIncome -5 -4 -30
Depreciation 0 0 0
DeferredIncomeT 0 0 0
StockBasedCompe 1 1 4
AccountsReceiva 0 0 0
InventoryCS 0 0 0
AccountsPayable 2 1 2
OtherWorkingCap -9 -7 4
OtherNonCashIte 1 1 2
NetCashProvided -10 -9 -19
InvestmentsInPP 0 0 0
AcquisitionsNet 0 0 0
PurchasesOfInve 0 0 -291
SalesMaturities 0 0 48
PurchasesOfInta 0 0 0
OtherInvestingA 0 0 0
NetCashUsedForI 0 0 -243
DebtIssued 0 10 0
DebtRepayment 0 0 0
CommonStockIssu 0 0 294
CommonStockRepu 0 0 0
DividendPaid 0 0 0
OtherFinancingA -1 -1 -2
NetCashProvided 39 9 292
NetChangeInCash 29 0 30
CashAtBeginning 22 52 51
CashAtEndOfPeri 52 51 81
AnaptysBio Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes AnaptysBio Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.